Literature DB >> 15070988

Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains.

Federico Román1, Rafael Cantón, María Pérez-Vázquez, Fernando Baquero, José Campos.   

Abstract

The persistence and variability of 188 Haemophilus influenzae isolates in respiratory tract of 30 cystic fibrosis (CF) patients over the course of 7 years was studied. Antibiotic susceptibility testing, DNA fingerprinting, and analysis of outer membrane protein profiles were performed on all isolates. A total of 115 distinct pulsed-field gel electrophoresis profiles were identified. Ninety percent of patients were cocolonized with two or more clones over the studied period. A third of the patients were cross-colonized with one or two H. influenzae strains; 11% of the clones persisted for 3 or more months. Biotype, outer membrane protein profiles, and resistance profiles showed variation along the studied period, even in persisting clones. Four isolates (2.1%) recovered from 3 patients were type f capsulate, with three of them belonging to the same clone. beta-Lactamase production was detected in 23.9% of isolates while 7% of the beta-lactamase-negative isolates presented diminished susceptibility to ampicillin (beta-lactamase-negative ampicillin resistance phenotype). Remarkably, 21.3% of the H. influenzae isolates presented decreased susceptibility to ciprofloxacin, which was mainly observed in persisting clones. Of the H. influenzae isolates from CF patients, 18 (14.5%) were found to be hypermutable in comparison with 1 (1.4%) from non-CF patients (P < 0.0001). Ten patients (33.3%) were colonized by hypermutable strains over the study period. A multiresistance phenotype and long-term clonal persistence were significantly associated in some cases for up to 7 years. These results suggest that H. influenzae bronchial colonization in CF patients is a dynamic process, but better-adapted clones can persist for long periods of time.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070988      PMCID: PMC387613          DOI: 10.1128/JCM.42.4.1450-1459.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

Review 1.  Persistent and aggressive bacteria in the lungs of cystic fibrosis children.

Authors:  C Anthony Hart; Craig Winstanley
Journal:  Br Med Bull       Date:  2002       Impact factor: 4.291

2.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

Authors:  A Oliver; R Cantón; P Campo; F Baquero; J Blázquez
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

3.  Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.

Authors:  Sylvia Valdezate; Ana Vindel; Aurora Echeita; Fernando Baquero; Rafael Cantó
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 4.  Pulmonary infections in patients with cystic fibrosis.

Authors:  Sujatha Rajan; Lisa Saiman
Journal:  Semin Respir Infect       Date:  2002-03

5.  Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999.

Authors:  F Marco; J García-de-Lomas; C García-Rey; E Bouza; L Aguilar; C Fernández-Mazarrasa
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.

Authors:  María Pérez-Vázquez; Federico Román; M Carmen Varela; Rafael Cantón; José Campos
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

7.  High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains.

Authors:  Anne-Laure Prunier; Brigitte Malbruny; Muriel Laurans; Jacques Brouard; Jean-François Duhamel; Roland Leclercq
Journal:  J Infect Dis       Date:  2003-05-15       Impact factor: 5.226

8.  Variation in the composition and pore function of major outer membrane pore protein P2 of Haemophilus influenzae from cystic fibrosis patients.

Authors:  A G Regelink; D Dahan; L V Möller; J W Coulton; P Eijk; P Van Ulsen; J Dankert; L Van Alphen
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

Review 9.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

10.  Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.

Authors:  S Valdezate; A Vindel; L Maiz; F Baquero; H Escobar; R Cantón
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

View more
  40 in total

1.  Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli.

Authors:  Erick Denamur; Olivier Tenaillon; Catherine Deschamps; David Skurnik; Esthel Ronco; Jean Louis Gaillard; Bertrand Picard; Catherine Branger; Ivan Matic
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

2.  Genomic sequence of an otitis media isolate of nontypeable Haemophilus influenzae: comparative study with H. influenzae serotype d, strain KW20.

Authors:  Alistair Harrison; David W Dyer; Allison Gillaspy; William C Ray; Rachna Mungur; Matthew B Carson; Huachun Zhong; Jenny Gipson; Mandy Gipson; Linda S Johnson; Lisa Lewis; Lauren O Bakaletz; Robert S Munson
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

3.  Identifying mutator phenotypes among fluoroquinolone-resistant strains of Streptococcus pneumoniae using fluctuation analysis.

Authors:  Carolyn V Gould; Paul D Sniegowski; Mikhail Shchepetov; Joshua P Metlay; Jeffrey N Weiser
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

4.  Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.

Authors:  María Pérez-Vázquez; Federico Román; Silvia García-Cobos; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

Review 5.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 6.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

Review 7.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

8.  DnaN clamp zones provide a platform for spatiotemporal coupling of mismatch detection to DNA replication.

Authors:  Justin S Lenhart; Anushi Sharma; Manju M Hingorani; Lyle A Simmons
Journal:  Mol Microbiol       Date:  2012-12-11       Impact factor: 3.501

9.  Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms.

Authors:  Timothy D Starner; Joshua D Shrout; Matthew R Parsek; Peter C Appelbaum; GunHee Kim
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

10.  The Haemophilus influenzae Sap transporter mediates bacterium-epithelial cell homeostasis.

Authors:  Forrest K Raffel; Blake R Szelestey; Wandy L Beatty; Kevin M Mason
Journal:  Infect Immun       Date:  2012-10-15       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.